Novel ligand for for quantification of synaptic density in brain (SV2A) now produced by PharmaSynth AS
PharmaSynth AS is now producing BF3-Dm-UCB-J, a precursor for[11C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.
For more information regarding the ligand activity and findings, please consult the publications:
Finnema, S. J. et.al., Sci Transl Med. 2016, vol 8, issue 348.
Nabulsi, N. B. et al., J Nucl Med. 2016, 57, 777-784.
Corresponding products in our portfolio:
For further information regarding technical specifications please contact Jukka Hiltunen at email@example.com or our chief chemist, Olavi Loog at firstname.lastname@example.org or by using the contact form on our webpage.